The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited

European Journal of Pharmacology

Volumn 753, Issue , 2015, Pages 114-126

  Van Enkhuizen, Jordy ^a,b   Janowsky, David S ^a   Olivier, Berend ^b   Minassian, Arpi ^a   Perry, William ^a   Young, Jared W ^a,c   Geyer, Mark A ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UTRECHT UNIVERSITY   (Netherlands)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Acetylcholine; Bipolar disorder; Depression; Dopamine; Mania; Mice

Indexed keywords

ACETYLCHOLINESTERASE; AMPHETAMINE; CITALOPRAM; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; FLUOXETINE; LITHIUM; MECAMYLAMINE; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; NORADRENALIN; PHYSOSTIGMINE; QUINPIROLE; SCOPOLAMINE; TETRAHYDROCANNABINOL; TYROSINE 3 MONOOXYGENASE; VALPROIC ACID; VANOXERINE; ACETYLCHOLINE; CATECHOLAMINE;

ACETYLCHOLINE RELEASE; ARTICLE; AUTOPSY; BIPOLAR DEPRESSION; BIPOLAR MANIA; CATECHOLAMINERGIC SYSTEM; CHOLINERGIC SYSTEM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; HYPERACTIVITY; MAJOR DEPRESSION; MOOD DISORDER; NONHUMAN; OBSERVATIONAL STUDY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; ANIMAL; BIPOLAR DISORDER; BRAIN; METABOLISM;

ACETYLCHOLINE; ANIMALS; BIPOLAR DISORDER; BRAIN; CATECHOLAMINES; HUMANS;

EID: 84925639553     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.05.063     Document Type: Article

References (176)

1. M. Adida, F. Jollant, L. Clark, N. Besnier, S. Guillaume, A. Kaladjian, P. Mazzola-Pomietto, R. Jeanningros, G.M. Goodwin, J.M. Azorin, and P. Courtet Trait-related decision-making impairment in the three phases of bipolar disorder Biol. Psychiatry 70 2011 357 365
2. J.D. Amsterdam, and A.B. Newberg A preliminary study of dopamine transporter binding in bipolar and unipolar depressed patients and healthy controls Neuropsychobiology 55 2007 167 170
3. A. Anand, P. Verhoeff, N. Seneca, S.S. Zoghbi, J.P. Seibyl, D.S. Charney, and R.B. Innis Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients Am. J. Psychiatry 157 2000 1108 1114
4. A. Anand, A. Darnell, H.L. Miller, R.M. Berman, A. Cappiello, D.A. Oren, S.W. Woods, and D.S. Charney Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder Biol. Psychiatry 45 1999 972 978
5. A. Anand, G. Barkay, M. Dzemidzic, D. Albrecht, H. Karne, Q.H. Zheng, G.D. Hutchins, M.D. Normandin, and K.K. Yoder Striatal dopamine transporter availability in unmedicated bipolar disorder Bipolar Disord. 13 2011 406 413
6. I. Ancin, A. Barabash, B. Vazquez-Alvarez, J.L. Santos, E. Sanchez-Morla, J.L. Martinez, A. Aparicio, J.C. Pelaez, and J.A. Diaz Evidence for association of the non-duplicated region of CHRNA7 gene with bipolar disorder but not with Schizophrenia Psychiatr. Genet. 20 2010 289 297
7. J.T. Andreasen, and J.P. Redrobe Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests Behav. Brain Res. 197 2009 150 156
8. J.T. Andreasen, and J.P. Redrobe Antidepressant-like effects of nicotine and mecamylamine in the mouse forced swim and tail suspension tests: role of strain, test and sex Behav. Pharmacol. 20 2009 286 295
9. J.T. Andreasen, J.P. Redrobe, and E.O. Nielsen Combined alpha7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987 Pharmacol. Biochem. Behav. 100 2012 624 629
10. J.T. Andreasen, G.M. Olsen, O. Wiborg, and J.P. Redrobe Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests J. Psychopharmacol. 23 2009 797 804
11. J.T. Andreasen, K. Henningsen, S. Bate, S. Christiansen, and O. Wiborg Nicotine reverses anhedonic-like response and cognitive impairment in the rat chronic mild stress model of depression: comparison with sertraline J. Psychopharmacol. 25 2011 1134 1141
12. I. Arai, Y. Tsuyuki, H. Shiomoto, M. Satoh, and S. Otomo Decreased body temperature dependent appearance of behavioral despair in the forced swimming test in mice Pharmacol. Res. 42 2000 171 176
13. F. Benedetti, A. Serretti, C. Colombo, B. Barbini, C. Lorenzi, E. Campori, and E. Smeraldi Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression Am. J. Med. Genet. Part B Neuropsychiatr. Genet.: Off. Publ. Int. Soc. Psychiatr. Genet. 123B 2003 23 26
14. M. Berk, S. Dodd, M. Kauer-Sant'anna, G.S. Malhi, M. Bourin, F. Kapczinski, and T. Norman Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder Acta Psychiatr. Scand. Suppl. 2007 41 49
15. M.B. Bowers Jr.; E. Goodman, and V.M. Sim Some behavioral changes in man following anticholinesterase administration J. Nerv. Ment. Dis. 138 1964 383 389
16. L.H. Brauer, and H. De Wit High dose pimozide does not block amphetamine-induced euphoria in normal volunteers Pharmacol. Biochem. Behav. 56 1997 265 272
17. H.K. Brodie, D.L. Murphy, F.K. Goodwin, and W.E. Bunney Jr. Catecholamines and mania: the effect of alpha-methyl-para-tyrosine on manic behavior and catecholamine metabolism Clin. Pharmacol. Ther. 12 1971 218 224
18. W.E. Bunney Jr.; and B.L. Garland A second generation catecholamine hypothesis Pharmacopsychiatria 15 1982 111 115
19. W.E. Bunney Jr.; H.K. Brodie, D.L. Murphy, and F.K. Goodwin Studies of alpha-methyl-para-tyrosine, l-dopa, and l-tryptophan in depression and mania Am. J. Psychiatry 127 1971 872 881
20. B. Cagniard, P.D. Balsam, D. Brunner, and X. Zhuang Mice with chronically elevated dopamine exhibit enhanced motivation, but not learning, for a food reward Neuropsychopharmacology 31 2006 1362 1370
21. D.M. Cannon, R.E. Carson, A.C. Nugent, W.C. Eckelman, D.O. Kiesewetter, J. Williams, D. Rollis, M. Drevets, S. Gandhi, G. Solorio, and W.C. Drevets Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder Arch. Gen. Psychiatry 63 2006 741 747
22. 2 receptor binding in vivo and accounts for reduced binding in bipolar disorder Mol. Psychiatry 16 2011 407 418
23. D.E. Casey Mood alterations during deanol therapy Psychopharmacology 62 1979 187 191
24. T.T. Chang, T.L. Yeh, N.T. Chiu, P.S. Chen, H.Y. Huang, Y.K. Yang, I.H. Lee, and R.B. Lu Higher striatal dopamine transporters in euthymic patients with bipolar disorder: a SPECT study with [Tc] TRODAT-1 Bipolar Disord. 12 2010 102 106
25. H.C. Charles, F. Lazeyras, K.R. Krishnan, O.B. Boyko, M. Payne, and D. Moore Brain choline in depression: in vivo detection of potential pharmacodynamic effects of antidepressant therapy using hydrogen localized spectroscopy Prog. Neuropsychopharmacol. Biol. Psychiatry 18 1994 1121 1127
26. S. Cichon, M.M. Nothen, G. Stober, R. Schroers, M. Albus, W. Maier, M. Rietschel, J. Korner, B. Weigelt, E. Franzek, D. Wildenauer, R. Fimmers, and P. Propping Systematic screening for mutations in the 5′-regulatory region of the human dopamine D1 receptor (DRD1) gene in patients with schizophrenia and bipolar affective disorder Am. J. Med. Genet. 67 1996 424 428
27. D.E. Comings, S. Wu, M. Rostamkhani, M. McGue, W.G. Iacono, and J.P. MacMurray Association of the muscarinic cholinergic 2 receptor (CHRM2) gene with major depression in women Am. J. Med. Genet. 114 2002 527 529
28. J.R. Cooper, R.H. Roth, and F.E. Bloom Biochem. Basis Neuropharmacol. 1991
29. L. Coque, S. Mukherjee, J.L. Cao, S. Spencer, M. Marvin, E. Falcon, M.M. Sidor, S.G. Birnbaum, A. Graham, R.L. Neve, E. Gordon, A.R. Ozburn, M.S. Goldberg, M.H. Han, D.C. Cooper, and C.A. McClung Specific role of VTA dopamine neuronal firing rates and morphology in the reversal of anxiety-related, but not depression-related behavior in the ClockDelta19 mouse model of mania Neuropsychopharmacology 36 2011 1478 1488
30. D.A. Cousins, K. Butts, and A.H. Young The role of dopamine in bipolar disorder Bipolar Disord. 11 2009 787 806
31. J.F. Cryan, C. Mombereau, and A. Vassout The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice Neurosci. Biobehav. Rev. 29 2005 571 625
32. G. Dagyte, J.A. Den Boer, and A. Trentani The cholinergic system and depression Behav. Brain Res. 221 2011 574 582
33. A. Das, K. Kapoor, A.T. Sayeepriyadarshini, M. Dikshit, G. Palit, and C. Nath Immobilization stress-induced changes in brain acetylcholinesterase activity and cognitive function in mice Pharmacol. Res. 42 2000 213 217
34. K.L. Davis, L.E. Hollister, and P.A. Berger Choline chloride in schizophrenia Am. J. Psychiatry 136 1979 1581 1584
35. K.L. Davis, P.A. Berger, L.E. Hollister, and E. Defraites Physostigmine in mania Arch. Gen. Psychiatry 35 1978 119 122
36. K.L. Davis, E. Hollander, M. Davidson, B.M. Davis, R.C. Mohs, and T.B. Horvath Induction of depression with oxotremorine in patients with Alzheimer's disease Am. J. Psychiatry 144 1987 468 471
37. D. Dencker, and H. Husum Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder Behav. Brain Res. 207 2010 78 83
38. A. Der-Avakian, M.S. D'Souza, D.A. Pizzagalli, and A. Markou Assessment of reward responsiveness in the response bias probabilistic reward task in rats: implications for cross-species translational research Transl. Psychiatry 3 2013 e297
39. S.C. Dilsaver, J.A. Peck, and D.H. Overstreet The Flinders sensitive line exhibits enhanced thermic responsiveness to nicotine relative to the Sprague-Dawley rat Pharmacol. Biochem. Behav. 41 1992 23 27
40. M. Dmitrzak-Weglarz, J.K. Rybakowski, A. Slopien, P.M. Czerski, A. Leszczynska-Rodziewicz, P. Kapelski, M. Kaczmarkiewicz-Fass, and J. Hauser Dopamine receptor D1 gene-48A/G polymorphism is associated with bipolar illness but not with schizophrenia in a polish population Neuropsychobiology 53 2006 46 50
41. T.N. Douma, A. Kolarz, Y. Postma, B. Olivier, and L. Groenink The amphetamine-chlordiazepoxide mixture, a pharmacological screen for mood stabilizers, does not enhance amphetamine-induced disruption of prepulse inhibition Behav. Brain Res. 225 2011 377 381
42. W.C. Drevets, and M.L. Furey Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial Biol. Psychiatry 67 2010 432 438
43. DSM-V Diagnostic and statistical manual of mental health disorders: DSM-5 5th ed. 2013 American Psychiatric Publishing Washington, DC
44. S. Dube, N. Kumar, E. Ettedgui, R. Pohl, D. Jones, and N. Sitaram Cholinergic REM induction response: separation of anxiety and depression Biol. Psychiatry 20 1985 408 418
45. D. Dulcis, P. Jamshidi, S. Leutgeb, and N.C. Spitzer Neurotransmitter switching in the adult brain regulates behavior Science 340 2013 449 453
46. R. Dunstan, and D.M. Jackson The demonstration of a change in responsiveness of mice to physostigmine and atropine after withdrawal from long-term haloperidol pretreatment J. Neural Transm. 40 1977 181 189
47. N. Egashira, Y. Matsumoto, K. Mishima, K. Iwasaki, M. Fujioka, M. Matsushita, Y. Shoyama, R. Nishimura, and M. Fujiwara Low dose citalopram reverses memory impairment and electroconvulsive shock-induced immobilization Pharmacol. Biochem. Behav. 83 2006 161 167
48. M.K. El-Yousef, D.S. Janowsky, J.M. Davis, and J.E. Rosenblatt Induction of severe depression by physostigmine in marihuana intoxicated individuals Br. J. Addict. Alcohol Other Drugs 68 1973 321 325
49. P. Fagergren, D.H. Overstreet, M. Goiny, and Y.L. Hurd Blunted response to cocaine in the Flinders hypercholinergic animal model of depression Neuroscience 132 2005 1159 1171
50. S.M. Ferguson, J.D. Brodkin, G.K. Lloyd, and F. Menzaghi Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression Psychopharmacology 152 2000 295 303
51. V.F. Ferreira, D.R. da Rocha, K.G. Lima Araujo, and W.C. Santos Advances in drug discovery to assess cholinergic neurotransmission: a systematic review Curr. Drug Discov. Technol. 5 2008 236 249
52. L. Ferrie, A.H. Young, and R. McQuade Effect of chronic lithium and withdrawal from chronic lithium on presynaptic dopamine function in the rat J. Psychopharmacol. 19 2005 229 234
53. L. Ferrie, A.H. Young, and R. McQuade Effect of lithium and lithium withdrawal on potassium-evoked dopamine release and tyrosine hydroxylase expression in the rat Int. J. Neuropsychopharmacol.: Off. Sci. J. Coll. Int. Neuropsychopharmacol. 9 2006 729 735
54. Frankel E.; Drevets W.; Luckenbaugh D.; Speer A.; Nugent A.; Zarate C.; Furey M.; 2011. In: Proceedings of the 9th International Conference on Bipolar Disorder, Pittsburgh, PA, Poster P58.
55. M.L. Furey, and W.C. Drevets Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial Arch. Gen. Psychiatry 63 2006 1121 1129
56. M.L. Furey, A. Khanna, E.M. Hoffman, and W.C. Drevets Scopolamine produces larger antidepressant and antianxiety effects in women than in men Neuropsychopharmacology 35 2010 2479 2488
57. P. Fusar-Poli, K. Rubia, G. Rossi, G. Sartori, and U. Balottin Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis Am. J. Psychiatry 169 2012 264 272
58. R.R. Gainetdinov, A.R. Mohn, L.M. Bohn, and M.G. Caron Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter Proc. Natl. Acad. Sci. USA 98 2001 11047 11054
59. A. Garakani, D.S. Chamey, and A. Anand Abnormalities in catecholamines and the pathophysiology of bipolar disorder J.C. Soares, A.H. Young, Bipolar Disorders: Basic Mechanisms and Therapeutic Implications 2 edition 2007 (In:)
60. G.J. Gatto, G.A. Bohme, W.S. Caldwell, S.R. Letchworth, V.M. Traina, M.C. Obinu, M. Laville, M. Reibaud, L. Pradier, G. Dunbar, and M. Bencherif TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects CNS Drug Rev. 10 2004 147 166
61. T.P. George, K.A. Sacco, J.C. Vessicchio, A.H. Weinberger, and R.D. Shytle Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study J. Clin. Psychopharmacol. 28 2008 340 344
62. R.H. Gerner, L. Fairbanks, G.M. Anderson, J.G. Young, M. Scheinin, M. Linnoila, T.A. Hare, B.A. Shaywitz, and D.J. Cohen CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls Am. J. Psychiatry 141 1984 1533 1540
63. S. Gershon, and F.H. Shaw Psychiatric sequelae of chronic exposure to organophosphorus insecticides Lancet 1 1961 1371 1374
64. A.S. Gibbons, E. Scarr, C. McLean, S. Sundram, and B. Dean Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects J. Affect. Disord. 116 2009 184 191
65. B. Giros, M. Jaber, S.R. Jones, R.M. Wightman, and M.G. Caron Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter Nature 379 1996 606 612
66. A.H. Glassman, J.E. Helzer, L.S. Covey, L.B. Cottler, F. Stetner, J.E. Tipp, and J. Johnson Smoking, smoking cessation, and major depression JAMA 264 1990 1546 1549
67. P.W. Gold, and G.P. Chrousos Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states Mol. Psychiatry 7 2002 254 275
68. A.M. Graybiel Neurotransmitters and neuromodulators in the basal ganglia Trends Neurosci. 13 1990 244 254
69. T.A. Greenwood, N.J. Schork, E. Eskin, and J.R. Kelsoe Identification of additional variants within the human dopamine transporter gene provides further evidence for an association with bipolar disorder in two independent samples Mol. Psychiatry 11 2006 125 133
70. T.A. Greenwood, M. Alexander, P.E. Keck, S. McElroy, A.D. Sadovnick, R.A. Remick, and J.R. Kelsoe Evidence for linkage disequilibrium between the dopamine transporter and bipolar disorder Am. J. Med. Genet. 105 2001 145 151
71. M.K. Hahn, and R.D. Blakely The functional impact of SLC6 transporter genetic variation Annu. Rev. Pharmacol. Toxicol. 47 2007 401 441
72. B.J. Hall, L.S. Pearson, and J.J. Buccafusco Effect of the use-dependent, nicotinic receptor antagonist BTMPS in the forced swim test and elevated plus maze after cocaine discontinuation in rats Neurosci. Lett. 474 2010 84 87
73. D.D. Han, and H.H. Gu Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs BMC Pharmacol. 6 2006 6
74. J.O. Hannestad, K.P. Cosgrove, N.F. Dellagioia, E. Perkins, F. Bois, Z. Bhagwagar, J.P. Seibyl, T.D. McClure-Begley, M.R. Picciotto, and I. Esterlis Changes in the cholinergic system between bipolar depression and euthymia as measured with [I]5IA single photon emission computed tomography Biol. Psychiatry 2013
75. G. Hasey, and I. Hanin The cholinergic-adrenergic hypothesis of depression reexamined using clonidine, metoprolol, and physostigmine in an animal model Biol. Psychiatry 29 1991 127 138
76. G. Hasler, W.C. Drevets, T.D. Gould, I.I. Gottesman, and H.K. Manji Toward constructing an endophenotype strategy for bipolar disorders Biol. Psychiatry 60 2006 93 105
77. B.L. Henry, A. Minassian, J.W. Young, M.P. Paulus, M.A. Geyer, and W. Perry Cross-species assessments of motor and exploratory behavior related to bipolar disorder Neurosci. Biobehav. Rev. 34 2010 1296 1306
78. C.J. Hong, I.C. Lai, L.L. Liou, and S.J. Tsai Association study of the human partially duplicated alpha7 nicotinic acetylcholine receptor genetic variant with bipolar disorder Neurosci. Lett. 355 2004 69 72
79. S. Horschitz, R. Hummerich, T. Lau, M. Rietschel, and P. Schloss A dopamine transporter mutation associated with bipolar affective disorder causes inhibition of transporter cell surface expression Mol. Psychiatry 10 2005 1104 1109
80. D. Jacobs, and T. Silverstone Dextroamphetamine-induced arousal in human subjects as a model for mania Psychol. Med. 16 1986 323 329
81. D.S. Janowsky Serendipity strikes again: scopolamine as an antidepressant agent in bipolar depressed patients Curr. Psychiatry Rep. 13 2011 443 445
82. D.S. Janowsky, M.K. el-Yousef, and J.M. Davis Acetylcholine and depression Psychosom. Med. 36 1974 248 257
83. D.S. Janowsky, D.H. Overstreet, and J.I. Nurnberger Jr. Is cholinergic sensitivity a genetic marker for the affective disorders? Am. J. Med. Genet. 54 1994 335 344
84. D.S. Janowsky, M.K. el-Yousef, J.M. Davis, and H.J. Sekerke A cholinergic-adrenergic hypothesis of mania and depression Lancet 2 1972 632 635
85. D.S. Janowsky, M.K. el-Yousef, J.M. Davis, and H.J. Sekerke Antagonistic effects of physostigmine and methylphenidate in man Am. J. Psychiatry 130 1973 1370 1376
86. D.S. Janowsky, K. el-Yousef, J.M. Davis, and H.J. Sekerke Parasympathetic suppression of manic symptoms by physostigmine Arch. Gen. Psychiatry 28 1973 542 547
87. D.S. Janowsky, C. Risch, D. Parker, L. Huey, and L. Judd Increased vulnerability to cholinergic stimulation in affective-disorder patients [proceedings] Psychopharmacol. Bull. 16 1980 29 31
88. D.S. Janowsky, S.C. Risch, B. Kennedy, M. Ziegler, and L. Huey Central muscarinic effects of physostigmine on mood, cardiovascular function, pituitary and adrenal neuroendocrine release Psychopharmacology 89 1986 150 154
89. J.R. Kelsoe, A.D. Sadovnick, H. Kristbjarnarson, P. Bergesch, Z. Mroczkowski-Parker, M. Drennan, M.H. Rapaport, P. Flodman, M.A. Spence, and R.A. Remick Possible locus for bipolar disorder near the dopamine transporter on chromosome 5 Am. J. Med. Genet. 67 1996 533 540
90. D. Khajavi, M. Farokhnia, A. Modabbernia, M. Ashrafi, S.H. Abbasi, M. Tabrizi, and S. Akhondzadeh Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study J. Clin. Psychiatry 73 2012 1428 1433
91. K. Krivisky, H. Einat, and N. Kronfeld-Schor Effects of morning compared with evening bright light administration to ameliorate short-photoperiod induced depression- and anxiety-like behaviors in a diurnal rodent model J. Neural Transm. 119 2012 1241 1248
92. U. Livneh, A. Dori, A. Katzav, and O. Kofman Strain and regional dependence of alternate splicing of acetylcholinesterase in the murine brain following stress or treatment with diisopropylfluorophosphate Behav. Brain Res. 210 2010 107 115
93. F.W. Lohoff, T.N. Ferraro, L. McNabb, C. Schwebel, J.P. Dahl, G.A. Doyle, R.J. Buono, and W.H. Berrettini No association between common variations in the neuronal nicotinic acetylcholine receptor alpha2 subunit gene (CHRNA2) and bipolar I disorder Psychiatry Res. 135 2005 171 177
94. R.T. Malison, S.E. Best, E.A. Wallace, E. McCance, M. Laruelle, S.S. Zoghbi, R.M. Baldwin, J.S. Seibyl, P.B. Hoffer, and L.H. Price Euphorigenic doses of cocaine reduce [123I]beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts Psychopharmacology 122 1995 358 362
95. O. Malkesman, D.R. Austin, G. Chen, and H.K. Manji Reverse translational strategies for developing animal models of bipolar disorder Dis. Model Mech. 2 2009 238 245
96. H.K. Manji, J.A. Quiroz, J.L. Payne, J. Singh, B.P. Lopes, J.S. Viegas, and C.A. Zarate The underlying neurobiology of bipolar disorder World Psychiatry 2 2003 136 146
97. M.M. Marinho, F.C. de Sousa, V.M. de Bruin, M.R. Vale, and G.S. Viana Effects of lithium, alone or associated with pilocarpine, on muscarinic and dopaminergic receptors and on phosphoinositide metabolism in rat hippocampus and striatum Neurochem. Int. 33 1998 299 306
98. G.P. Mark, S. Shabani, L.K. Dobbs, and S.T. Hansen Cholinergic modulation of mesolimbic dopamine function and reward Physiol. Behav. 104 2011 76 81
99. A. Markou, and P.J. Kenny Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories Neurotox. Res. 4 2002 297 313
100. A. Markou, T.R. Kosten, and G.F. Koob Neurobiological similarities in depression and drug dependence: a self-medication hypothesis Neuropsychopharmacology 18 1998 135 174
101. A. Markou, K. Matthews, D.H. Overstreet, G.F. Koob, and M.A. Geyer Flinders resistant hypocholinergic rats exhibit startle sensitization and reduced startle thresholds Biol. Psychiatry 36 1994 680 688
102. M. Mavrikaki, G.G. Nomikos, and G. Panagis Efficacy of the atypical antipsychotic aripiprazole in d-amphetamine-based preclinical models of mania Int. J. Neuropsychopharmacol.: Off. Sci. J. Coll. Int. Neuropsychopharmacol. 13 2010 541 548
103. C.A. McClung, K. Sidiropoulou, M. Vitaterna, J.S. Takahashi, F.J. White, D.C. Cooper, and E.J. Nestler Regulation of dopaminergic transmission and cocaine reward by the Clock gene Proc. Natl. Acad. Sci. USA 102 2005 9377 9381
104. P. McGonigle Animal models of CNS disorders Biochem. Pharmacol. 87 2014 140 149
105. S.F. McTavish, P.J. Cowen, and T. Sharp Effect of a tyrosine-free amino acid mixture on regional brain catecholamine synthesis and release Psychopharmacology 141 1999 182 188
106. S.F. McTavish, M.H. McPherson, T. Sharp, and P.J. Cowen Attenuation of some subjective effects of amphetamine following tyrosine depletion J. Psychopharmacol. 13 1999 144 147
107. S.F. McTavish, M.H. McPherson, C.J. Harmer, L. Clark, T. Sharp, G.M. Goodwin, and P.J. Cowen Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness Br. J. Psychiatry 179 2001 356 360
108. K.R. Merikangas, R. Jin, J.P. He, R.C. Kessler, S. Lee, N.A. Sampson, M.C. Viana, L.H. Andrade, C. Hu, E.G. Karam, M. Ladea, M.E. Medina-Mora, Y. Ono, J. Posada-Villa, R. Sagar, J.E. Wells, and Z. Zarkov Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative Arch. Gen. Psychiatry 68 2011 241 251
109. E. Meyendorff, B. Lerer, N.C. Moore, J. Bow, and S. Gershon Methylphenidate infusion in euthymic bipolars: effect of carbamazepine pretreatment Psychiatry Res. 16 1985 303 308
110. A. Minassian, J.R. Kelsoe, M.P. Paulus, M.A. Geyer, and W. Perry Associations between COMTValMet genotype and clinical and cognitive phenotypes in manic bipolar patients Schizophr. Bull. 35 2009 109 110
111. Y.S. Mineur, O. Somenzi, and M.R. Picciotto Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice Neuropharmacology 52 2007 1256 1262
112. Y.S. Mineur, A. Obayemi, M.B. Wigestrand, G.M. Fote, C.A. Calarco, A.M. Li, and M.R. Picciotto Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior Proc. Natl. Acad. Sci. USA 110 2013 3573 3578
113. J. Modestin, R.B. Schwartz, and J. Hunger [Investigation about an influence of physostigmine on schizophrenic symptoms (author's transl)] Pharmakopsychiatr. Neuropsychopharmakol. 6 1973 300 304
114. J. Modestin, J. Hunger, and R.B. Schwartz [Depressive effects of physostigmine] Arch. Psychiatr. Nervenkrankh. 218 1973 67 77
115. X. Ni, J.M. Trakalo, E. Mundo, F.M. Macciardi, S. Parikh, L. Lee, and J.L. Kennedy Linkage disequilibrium between dopamine D1 receptor gene (DRD1) and bipolar disorder Biol. Psychiatry 52 2002 1144 1150
116. 2 receptor genes and bipolar affective disorder Am. J. Psychiatry 149 1992 199 201
117. D.M. Novick, H.A. Swartz, and E. Frank Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence Bipolar Disord. 12 2010 1 9
118. J.I. Nurnberger Jr.; D.C. Jimerson, S. Simmons-Alling, C. Tamminga, N.S. Nadi, D. Lawrence, N. Sitaram, J.C. Gillin, and E.S. Gershon Behavioral, physiological, and neuroendocrine responses to arecoline in normal twins and "well state" bipolar patients Psychiatry Res. 9 1983 191 200
119. G. Oppenheim, R.P. Ebstein, and R.H. Belmaker Effect of lithium on the physostigmine-induced behavioral syndrome and plasma cyclic GMP J. Psychiatr. Res. 15 1979 133 138
120. G. Orpen, and M. Steiner The WAGxDA rat: an animal model of cholinergic supersensitivity Biol. Psychiatry 37 1995 874 883
121. U. Osby, L. Brandt, N. Correia, A. Ekbom, and P. Sparen Excess mortality in bipolar and unipolar disorder in Sweden Arch. Gen. Psychiatry 58 2001 844 850
122. D.H. Overstreet The Flinders sensitive line rats: a genetic animal model of depression Neurosci. Biobehav. Rev. 17 1993 51 68
123. 2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder Arch. Gen. Psychiatry 52 1995 471 477
124. M. Peet, and S. Peters Drug-induced mania Drug Saf. 12 1995 146 153
125. W. Perry, A. Minassian, M.P. Paulus, J.W. Young, M.J. Kincaid, E.J. Ferguson, B.L. Henry, X. Zhuang, V.L. Masten, R.F. Sharp, and M.A. Geyer A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men Arch. Gen. Psychiatry 66 2009 1072 1080
126. B. Petit-Demouliere, F. Chenu, and M. Bourin Forced swimming test in mice: a review of antidepressant activity Psychopharmacology 177 2005 245 255
127. J.K. Pinsonneault, D.D. Han, K.E. Burdick, M. Kataki, A. Bertolino, A.K. Malhotra, H.H. Gu, and W. Sadee Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder Neuropsychopharmacology 36 2011 1644 1655
128. S.B. Powell, J.W. Young, J.C. Ong, M.G. Caron, and M.A. Geyer Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice Behav. Pharmacol. 19 2008 562 565
129. R.L. Rabenstein, B.J. Caldarone, and M.R. Picciotto The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice Psychopharmacology 189 2006 395 401
130. R.J. Ralph-Williams, M.P. Paulus, X. Zhuang, R. Hen, and M.A. Geyer Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system Biol. Psychiatry 53 2003 352 359
131. 2 receptor antagonists J. Neurosci. 21 2001 305 313
132. J.S. Rao, M. Kellom, E.A. Reese, S.I. Rapoport, and H.W. Kim Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients J. Affect. Disord. 136 2012 63 71
133. S.C. Risch, R.M. Cohen, D.S. Janowsky, N.H. Kalin, N. Sitaram, J.C. Gillin, and D.L. Murphy Physostigmine induction of depressive symptomatology in normal human subjects Psychiatry Res. 4 1981 89 94
134. M. Rivalan, S.H. Ahmed, and F. Dellu-Hagedorn Risk-prone individuals prefer the wrong options on a rat version of the Iowa Gambling Task Biol. Psychiatry 66 2009 743 749
135. H. Rollema, V. Guanowsky, Y.S. Mineur, A. Shrikhande, J.W. Coe, P.A. Seymour, and M.R. Picciotto Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect Eur. J. Pharmacol. 605 2009 114 116
136. M.A. Roni, and S. Rahman The effects of lobeline on nicotine withdrawal-induced depression-like behavior in mice Psychopharmacology 2014
137. D.W. Rowntree, S. Nevin, and A. Wilson The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis J. Neurol. Neurosurg. Psychiatry 13 1950 47 62
138. K. Roybal, D. Theobold, A. Graham, J.A. DiNieri, S.J. Russo, V. Krishnan, S. Chakravarty, J. Peevey, N. Oehrlein, S. Birnbaum, M.H. Vitaterna, P. Orsulak, J.S. Takahashi, E.J. Nestler, W.A. Carlezon Jr.; and C.A. McClung Mania-like behavior induced by disruption of CLOCK Proc. Natl. Acad. Sci. USA 104 2007 6406 6411
139. V. Salvi, A. Fagiolini, H.A. Swartz, G. Maina, and E. Frank The use of antidepressants in bipolar disorder J. Clin. Psychiatry 69 2008 1307 1318
140. A. Saricicek, I. Esterlis, K.H. Maloney, Y.S. Mineur, B.M. Ruf, A. Muralidharan, J.I. Chen, K.P. Cosgrove, R. Kerestes, S. Ghose, C.A. Tamminga, B. Pittman, F. Bois, G. Tamagnan, J. Seibyl, M.R. Picciotto, J.K. Staley, and Z. Bhagwagar Persistent beta2-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder Am. J. Psychiatry 169 2012 851 859
141. A. Serretti, F. Benedetti, L. Mandelli, C. Lorenzi, A. Pirovano, C. Colombo, and E. Smeraldi Genetic dissection of psychopathological symptoms: insomnia in mood disorders and CLOCK gene polymorphism Am. J. Med. Genet. Part B Neuropsychiatr. Genet.: Off. Publ. Int. Soc. Psychiatr. Genet. 121B 2003 35 38
142. A. Shaldubina, H. Einat, H. Szechtman, H. Shimon, and R.H. Belmaker Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder J. Neural Transm. 109 2002 433 440
143. J.A. Sherman Evolutionary origin of bipolar disorder-revised: EOBD-R Med. Hypotheses 78 2012 113 122
144. R.D. Shytle, A.A. Silver, and P.R. Sanberg Comorbid bipolar disorder in Tourette's syndrome responds to the nicotinic receptor antagonist mecamylamine (Inversine) Biol. Psychiatry 48 2000 1028 1031
145. R.D. Shytle, A.A. Silver, R.J. Lukas, M.B. Newman, D.V. Sheehan, and P.R. Sanberg Nicotinic acetylcholine receptors as targets for antidepressants Mol. Psychiatry 7 2002 525 535
146. P.H. Silverstone, A. Pukhovsky, and S. Rotzinger Lithium does not attenuate the effects of d-amphetamine in healthy volunteers Psychiatry Res. 79 1998 219 226
147. T. Silverstone Response to bromocriptine distinguishes bipolar from unipolar depression Lancet 1 1984 903 904
148. T. Silverstone, J. Fincham, B. Wells, and M. Kyriakides The effect of the dopamine receptor blocking drug pimozide on the stimulant and anorectic actions of dextroamphetamine in man Neuropharmacology 19 1980 1235 1237
149. N. Sitaram, S. Dube, M. Keshavan, A. Davies, and P. Reynal The association of supersensitive cholinergic REM-induction and affective illness within pedigrees J. Psychiatr. Res. 21 1987 487 497
150. R. Sjostrom, and B.E. Roos 5-Hydroxyindolacetic acid and homovanillic acid in cerebrospinal fluid in manic-depressive psychosis Eur. J. Clin. Pharmacol. 4 1972 170 176
151. S. Spencer, M.I. Torres-Altoro, E. Falcon, R. Arey, M. Marvin, M. Goldberg, J.A. Bibb, and C.A. McClung A mutation in CLOCK leads to altered dopamine receptor function J. Neurochem. 123 2012 124 134
152. B.N. Srikumar, T.R. Raju, and B.S. Shankaranarayana Rao The involvement of cholinergic and noradrenergic systems in behavioral recovery following oxotremorine treatment to chronically stressed rats Neuroscience 143 2006 679 688
153. R.J. Steingard, D.A. Yurgelun-Todd, J. Hennen, J.C. Moore, C.M. Moore, K. Vakili, A.D. Young, A. Katic, W.R. Beardslee, and P.F. Renshaw Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy Biol. Psychiatry 48 2000 1053 1061
154. S. Subrahmanyam Role of biogenic amines in certain pathological conditions Brain Res. 87 1975 355 362
155. T. Suhara, K. Nakayama, O. Inoue, H. Fukuda, M. Shimizu, A. Mori, and Y. Tateno D1 dopamine receptor binding in mood disorders measured by positron emission tomography Psychopharmacology 106 1992 14 18
156. Sunanda, B.S. Rao, and T.R. Raju Restraint stress-induced alterations in the levels of biogenic amines, amino acids, and AChE activity in the hippocampus Neurochem. Res. 25 2000 1547 1552
157. J. van Enkhuizen, A. Minassian, and J.W. Young Further evidence for ClockDelta19 mice as a model for bipolar disorder mania using cross-species tests of exploration and sensorimotor gating Behav. Brain Res. 249 2013 44 54
158. J. van Enkhuizen, M.A. Geyer, and J.W. Young Differential effects of dopamine transporter inhibitors in the rodent Iowa gambling task: relevance to mania Psychopharmacology 225 2013 661 674
159. J. van Enkhuizen, M.A. Geyer, K. Kooistra, and J.W. Young Chronic valproate attenuates some, but not all, facets of mania-like behaviour in mice Int. J. Neuropsychopharmacol.: Off. Sci. J. Coll. Int. Neuropsychopharmacol. 16 2013 1021 1031
160. J. van Enkhuizen, M.A. Geyer, A.L. Halberstadt, X. Zhuang, and J.W. Young Dopamine depletion attenuates some behavioral abnormalities in a hyperdopaminergic mouse model of bipolar disorder J. Affect. Disord. 155 2014 247 254
161. D.P. Van Kammen, and D.L. Murphy Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment Psychopharmacologia 44 1975 215 224
162. R.B. Varela, S.S. Valvassori, J. Lopes-Borges, D.B. Fraga, W.R. Resende, C.O. Arent, A.I. Zugno, and J. Quevedo Evaluation of acetylcholinesterase in an animal model of mania induced by d-amphetamine Psychiatry Res. 2012
163. R.A. Vaughan, and J.D. Foster Mechanisms of dopamine transporter regulation in normal and disease states Trends Pharmacol. Sci. 34 2013 489 496
164. M.P. Vawter, W.J. Freed, and J.E. Kleinman Neuropathology of bipolar disorder Biol. Psychiatry 48 2000 486 504
165. B. Wang, and D. Chen Evidence for seasonal mania: a review J. Psychiatr. Pract. 19 2013 301 308
166. J. Wang, S.K. Michelhaugh, and M.J. Bannon Valproate robustly increases Sp transcription factor-mediated expression of the dopamine transporter gene within dopamine cells Eur. J. Neurosci. 25 2007 1982 1986
167. J.C. Wang Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome Hum. Mol. Genet. 13 2004 1903 1911
168. D.F. Wong, G.D. Pearlson, L.E. Tune, L.T. Young, C.C. Meltzer, R.F. Dannals, H.T. Ravert, J. Reith, M.J. Kuhar, and A. Gjedde Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness J. Cereb. Blood Flow Metab. 17 1997 331 342
169. L.N. Yatham, P.F. Liddle, R.W. Lam, I.S. Shiah, C. Lane, A.J. Stoessl, V. Sossi, and T.J. Ruth PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania Am. J. Psychiatry 159 2002 1718 1723
170. J.W. Young, X. Zhou, and M.A. Geyer Animal models of schizophrenia Curr. Top. Behav. Neurosci. 4 2010 391 433
171. J.W. Young, B.L. Henry, and M.A. Geyer Predictive animal models of mania: hits, misses and future directions Br. J. Pharmacol. 164 2011 1263 1284
172. J.W. Young, J. van Enkhuizen, C.A. Winstanley, and M.A. Geyer Increased risk-taking behavior in dopamine transporter knockdown mice: further support for a mouse model of mania J. Psychopharmacol. 25 2011 934 943
173. J.W. Young, A.K. Goey, A. Minassian, W. Perry, M.P. Paulus, and M.A. Geyer The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration Pharmacol. Biochem. Behav. 96 2010 7 15
174. J.W. Young, A.K. Goey, A. Minassian, W. Perry, M.P. Paulus, and M.A. Geyer GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior Psychopharmacology 208 2010 443 454
175. C.A. Zarate Jr.; J.L. Payne, J. Singh, J.A. Quiroz, D.A. Luckenbaugh, K.D. Denicoff, D.S. Charney, and H.K. Manji Pramipexole for bipolar II depression: a placebo-controlled proof of concept study Biol. Psychiatry 56 2004 54 60
176. K. Zavitsanou, A. Katsifis, Y. Yu, and X.F. Huang M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders Brain Res. Bull. 65 2005 397 403